Johnson & Johnson Gets $2.1B Offer For LifeScan Diabetes Device Unit

Johnson & Johnson JNJ announced that it has received a binding offer of approximately $2.1 billion from a private equity firm, Platinum Equity, for its LifeScan diabetes device unit. The LifeScan unit makes blood glucose monitoring products and generated revenues of $1.5 billion last year.

J&J stock has declined 3.8% this year so far, which compares unfavorably with a gain of 1.2% recorded by the industry.

J&J has time until Jun 15 to accept the offer, failing which it will expire. If J&J accepts the offer, the transaction is expected to close by the end of the year.

Sales in J&J's Diabetes Care franchise declined 9.7% in 2017 to $1.6 billion due to price decline and competitive pressure.

J&J has been evaluating potential strategic options for its Diabetes Care Units specifically, LifeScan, Animas Corporation, and Calibra Medical since early last year. In fact, in October, J&J announced that it will close operations of its Animas Corporation diabetes care unit and exit its insulin pump business. Animas will stop manufacturing Animas Vibe and OneTouch Ping insulin pumps. J&J said that per a deal with medical device maker, Medtronic, Inc. MDT, patients using an Animas insulin pump will be offered the option to transfer to a Medtronic pump.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsM&Acontributorcontributors
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!